Latest Conference Articles

The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.

Post-Progression Data Establishes Osimertinib as Frontline Standard of Care for EGFR-Mutant NSCLC

April 14th 2018, 10:18pm

European Lung Cancer Congress

First-line treatment with osimertinib resulted in a clinically meaningful delay in time from randomization to second progression on subsequent treatment or death, establishing the agent as a new standard of care in the frontline setting for patients with EGFR-mutant non–small cell lung cancer.

Dr. Besse Discusses Challenges Facing Stage IV NSCLC

April 13th 2018, 11:35pm

European Lung Cancer Congress

Benjamin Besse, MD, Institut Gustave Roussy, Villejuif, Paris Sud University, discusses challenges facing the treatment of patients with stage IV non

Dr. Reck on the Rationale of the IMpower150 Trial in NSCLC

April 13th 2018, 11:33pm

European Lung Cancer Congress

Martin Reck, MD, Department of Thoracic Oncology, Lung Clinic Grosshansdorf, discusses the IMpower150 trial data for patients with non

Necitumumab/Abemaciclib Combo Fails in Stage IV NSCLC

April 13th 2018, 11:31pm

European Lung Cancer Congress

A phase Ib study of necitumumab in combination with abemaciclib failed to meaningfully improve outcomes in patients with stage IV non–small cell lung cancer.

Osimertinib Prevents CNS Progression in Advanced NSCLC in a Real-World Setting

April 13th 2018, 9:31pm

European Lung Cancer Congress

Patients with advanced non–small cell lung cancer and baseline central nervous system metastasis showed control of their CNS metastasis after receiving osimertinib in a real-world clinical setting.

Nivolumab Benefit Unresolved in Unresectable or Recurrent Thymic Cancer

April 13th 2018, 7:46pm

European Lung Cancer Congress

Researchers from Japan recommended against further development of nivolumab for patients with previously treated unresectable or recurrent thymic carcinoma based on their findings from the phase II PRIMER study.

Frontline Osimertinib Controls Symptoms for Patients With EGFR-Mutated NSCLC

April 13th 2018, 7:31pm

European Lung Cancer Congress

Frontline treatment with osimertinib led to similar improvements in quality of life, including a clinically meaningful improvement in cough, compared with a standard of care EGFR TKIs for patients with advanced EGFR-mutant non–small cell lung cancer.

Dr. Perol Discusses Results of the ALEX Trial in ALK+ NSCLC

April 12th 2018, 8:54pm

European Lung Cancer Congress

Maurice Perol, MD, medical oncologist, Centre Leon Berard, discusses the results of the ALEX trial in ALK-positive non–small cell lung cancer.

Dr. Garon Discusses the CheckMate-384 Study in NSCLC

April 12th 2018, 8:52pm

European Lung Cancer Congress

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses the CheckMate-384 study in non–small cell lung cancer.

Dr. Garassino on QoL Findings from the FLAURA Study in NSCLC

April 12th 2018, 8:51pm

European Lung Cancer Congress

Marina Chiara Garassino, MD, medical consultant in the Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses the quality of life findings from the FLAURA study in non–small cell lung cancer.

Alectinib Edge Over Crizotinib Supported by Patient-Reported Outcomes

April 12th 2018, 8:03pm

European Lung Cancer Congress

In findings consistent with earlier results on efficacy and adverse events reported for the phase III ALEX trial, investigators announced superior patient-reported outcomes for the next-generation tyrosine kinase inhibitor alectinib versus the standard of care TKI inhibitor crizotinib in ALK-positive non–small cell lung cancer.

Frontline Atezolizumab Combo Emerges as Potential New Standard in NSCLC

April 12th 2018, 7:36pm

European Lung Cancer Congress

The frontline regimen of atezolizumab (Tecentriq), bevacizumab (Avastin), carboplatin, and paclitaxel has emerged as a potential new standard of care for the treatment of patients with metastatic nonsquamous NSCLC.

Atezolizumab Shines in Long-term POPLAR Findings

April 12th 2018, 6:07pm

European Lung Cancer Congress

Anti PD-L1 immunotherapy with atezolizumab (Tecentriq) was strongly superior to docetaxel in locally advanced or metastatic non–small cell lung cancer, according to 3-year survival findings from the phase II POPLAR study.

Similar Efficacy Across PARP Inhibitors in Ovarian Cancer, But Safety Analysis Favors Olaparib

March 28th 2018, 5:38am

SGO Annual Meeting

Currently approved PARP inhibitors have demonstrated similar efficacy in the setting of maintenance therapy for patients with ovarian cancer but differ with respect to the type and frequency of grade 3/4 adverse events, results of a network meta-analysis suggested.

Olaparib/Durvalumab Combo Active in Relapsed Ovarian Cancer

March 27th 2018, 11:36pm

SGO Annual Meeting

Combination therapy with the PARP inhibitor olaparib and the PD-L1 inhibitor durvalumab induced objective responses in more than 70% of patients with relapsed, platinum-sensitive, BRCA-mutated ovarian cancer.

Dr. Slomovitz Discusses a Study of Everolimus/Letrozole or Hormonal Therapy in Endometrial Cancer

March 27th 2018, 10:14pm

SGO Annual Meeting

Brian M. Slomovitz, MD, gynecologic oncologist, Sylvester Comprehensive Cancer Center, University of Miami, discusses GOG 3007, a randomized phase II study of everolimus (Afinitor) and letrozole or hormonal therapy (medroxyprogesterone acetate/tamoxifen) in women with advanced, persistent or recurrent endometrial carcinoma during the 2018 Society of Gynecologic Oncology Annual Meeting.

Dr. Mark Discusses an Ultra-Restrictive Opioid Prescription Protocol in Postoperative Patients

March 27th 2018, 8:06pm

SGO Annual Meeting

Jaron Mark, MD, gynecologic oncology fellow, Roswell Park Comprehensive Cancer Center, discusses the implementation of an ultra-restrictive opioid prescription protocol (UROPP) in patients undergoing major gynecologic surgery, which radically decreased dispensed opioids without reducing pain control, during the 2018 Society of Gynecologic Oncology Annual Meeting.

Pembrolizumab Plus Niraparib Shows Promise in Ovarian Cancer

March 27th 2018, 7:27pm

SGO Annual Meeting

Patients with platinum-resistant/refractory ovarian cancer had durable responses with the combination of the PARP inhibitor niraparib (Zejula) and pembrolizumab (Keytruda).

Pembrolizumab Plus Mirvetuximab Soravtansine Active in Ovarian Cancer

March 27th 2018, 12:38am

SGO Annual Meeting

Almost half of patients with platinum-resistant ovarian cancer had objective responses to combination therapy with pembrolizumab plus the antifolate antibody-drug conjugate mirvetuximab soravtansine.

Dr. Parsons Discusses the Role of PARP 7 in Overall Survival of Patients With Ovarian Cancer

March 26th 2018, 9:11pm

SGO Annual Meeting

Lavanya Palavalli Parsons, MD, clinical fellow, The University of Texas Southwestern Medical Center, discusses the role of PARP 7 in overall survival of patients with ovarian cancer during the 2018 Society of Gynecologic Oncology Annual Meeting.